PHARMACOLOGICAL CORRECTION OF HEART RATE IN MYOCARDIAL ISCHEMIA


Cite item

Full Text

Abstract

Cardiovascular diseases is one of the key causes of lethality in developed countries. Coronary heart disease and arterial hypertension make significant contribution to this lethality. The above two diseases are often accompanied with compensatory acceleration of the heart rate (HR). At the same time long-term tachycardia is an independent risk factor of complications resultant from high consumption of oxygen, disturbed energy metabolism in cardiomyocytes, regress of heart contractility, development of cardiac failure. Heart contraction rhythm depends on electric activity of the sinus node cells which spontaneously generate action potentials (AP) present in all heart compartments and triggering contractile activity of cardiomyocytes. The study of the pacemaker cells (pC) discovered not only mechanisms responsible for AP rise and HR physiological regulation but revealed new ionic channels —f-channels involved in acceleration and lowering of the heart rate. Reduction of current along the f-channels (If-current) lowers AP generation in PC and, therefore, HR. Three groups of medicines are now used for HR lowering : beta-adrenoblockers, non-dihydropyridine calcium antagonists and recently introduced into clinical practice innovative drug ivabradin (coraxan) selectively suppressing activity of f-channels of sinus node cells and thus lowering HR. The review analyses differences in mechanisms of a negative chronotropic effect of these drugs.

About the authors

E I Astashkin

I.M. Sechenov First Moscow State Medical University

д-р биол. наук, проф., зав. лаб. экстремальных состояний НИЦ Первого МГМУ им. И. М. Сеченова

M G Glezer

I.M. Sechenov First Moscow State Medical University

Email: 287ast@mail.ru
д-р мед. наук, проф., зав. лаб функциональных методов исследования и рациональной фармакотерапии НИЦ Первого МГМУ им. И. М. Сеченова

References

  1. Асташкин Е. И., Глезер М. Г. Пейсмекерные f-каналы миоцитов синусового узла, как новая терапевтическая мишень для снижения частоты сердечных сокращений. Кардиоваск. тер. и профилакт. 2007; 6 (8): 106—115.
  2. Silverman M. E., Grove D., Upshaw C. B. J. Why does the heart beat? The discovery of the electrical system of the heart. Circulation 2006; 113: 2775—2781.
  3. DiFrancesco D. Funny channels in the control of cardic rhythm and mode of action of selective blockers. Pharmacol. Res. 2006; 53: 399—406.
  4. DiFrancesco D. The role of the funny current in pacemaker activity. Circ. Res. 2010; 106: 434—446.
  5. Lakatta E. G., DiFrancesco D. What keeps us ticking: a funny current, a calcium clock, or both? J. Mol. Cell Cardiol. 2009; 47: 157—170.
  6. Vinogradova T. M., Bogdanov K. Y., Lakatta E. G. b-Adrenergic stimulation modulates ryanodine receptor Ca2+ release during diastolic depolarization to accelerate pacemaker activity in rabbit sinoatrial nodal cells. Circ. Res. 2002; 90: 73—79.
  7. Bucchi A., Baruscotti M., Robinson R. B., DiFrancesco D. I(f)-dependent modulation of pacemaker rate mediated by цАМФ in the presence of ryanodine in rabbit sinoatrial node cells. J. Mol. Cell Cardiol. 2003; 35: 905—913.
  8. Bucchi A., Baruscotti M., Robinson R. B., DiFrancesco D. Modulation of rate by autonomic agonists in SAN cells involves changes in diastolic depolarization and the pacemaker current. J. Mol. Cell Cardiol. 2007; 43: 39—48.
  9. Bers D. M. Calcium and cardiac rhythms. Physiological and pathophysiological. Circ. Res. 2002; 90: 14—16.
  10. Baruscotti M., Bucchi A., DiFrancesco D. Physiology and pharmacology of the cardiac pacemaker ("funny") current. Pharmacol. Ther. 2005; 107: 59—79.
  11. Maltsev V. A., Lakatta E. G. Dynamic interactions of an intracellular Ca2+ clock and membrane ion channel clock underlie robust initiation and regulation of cardiac pacemaker function. Cardiovasc. Res. 2008; 77: 274—284.
  12. Bogdanov K. Y., Vinogradova T. M., Lakatta E. G. Sinoatrial nodal cell ryanodine receptor and Na+—Ca2+ exchanger: molecular partners in pacemaker regulation. Circ. Res. 2001; 88: 1254—1258.
  13. Barbuti A., Baruscotti M., DiFrancesco D. The pacemaker current: from basics to the clinics. J. Cardiovasc. Electrophysiol. 2007: 18: 342—347.
  14. DiFrancesco D., Camm J. A. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs 2004; 64: 1757—1765.
  15. Bucchi A., Baruscotti M., DiFrancesco D. Current-dependent block of rabbit sinoatrial node I(f) channels by ivabradine. J. Gen. Physiol. 2002; 120: 1—13.
  16. DiFrancesco D., Borer J. S. The funny current. Cellular basis for the control of heart rate. Drugs 2007; 67 (Suppl. 2): 15—24.
  17. Tardif J. C., Ponikowski P., Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur. Heart J. 2009; 30: 540—548.
  18. Lipsius S. L., Huser J., Blatter L. A. Intracellular Ca2+ release sparks atrial pacemaker activity. News Physiol. Sci. 2001; 16: 101—106.
  19. Ceconi C., Cargnoni A., Francolini G. et al. Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart. Cardiovasc. Res. 2009; 84: 72—82.
  20. Borer J. S., Fox K., Jaillon P., Lerebours G. for the European Iv-abradine Investigators. Anti-anginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, doubleblinded, multicentered, placebo-controlled trial. Circulation 2003; 107: 817—823.
  21. Tardif J. C., Ford I., Tendera M., Bourassa M. G. for the Initiative Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared wit atenolol in patients with chronic stable angina. Eur. Heart J. 2005; 26: 2529—2536.
  22. Ruzyllo W., Ford I., Tendera M. et al. Antianginal and anti-ischemic effects of ivabradin compared to amlodipine in patients with stable effort angina: a 3-month randomized, double-blind, multicentre, noninferiority trial. Drugs 2007; 67: 393—405.
  23. Simon L., Glaleh B., Puybasset L. et al. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J. Pharmacol. Exp. Ther. 1995; 275 (2): 659—666.
  24. Tardif J. C., Ponikowski P., Kahan T. ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur. Heart J. 2009; 30 (5): 540—548.
  25. Глезер М. Г., Сайгитов Р. Т. от имени участников исследования КОНТРОЛЬ. Антиангинальная эффективность и переносимость ивабрадина в терапии пациентов со стабильной стенокардией: результаты исследования КОНТРОЛЬ (Кораксан в комбиНированной Терапии с бета-адреноблокатором у пациентов со стабиЛЬной стенокардией. Антиангинальная эффективность и переносимость). Кардиология 2010; 11: 65—75.
  26. Von Arnim T. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up. J. Am. Coll. Cardiol. 1996; 28 (1): 20—24.
  27. Карпов Ю. А. Программа АЛЬТЕРНАТИВА — исследование АнтиангинаЛЬной эффекТивности и пЕРеносимости КораксанА (ивабрадина) и оценка качества жизни пациентов со стабильной стенокардией. Сердце 2007; 2 (6): 102—104.
  28. Fox K., Ford I., Steg P. G. et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372 (9641): 807—816.
  29. Böhm M., Swedberg K., Komajda M. et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcome in a randomised placebo-controlled trial. Lancet 2010; 376 (9744): 886—894.
  30. Fox K., Ford I., Steg P. G. et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur. Heart J. 2009; 30 (19): 2337—2345.
  31. Swedberg K., Komajda M., Bohm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875—885.

Copyright (c) 2012 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies